Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

OBJECTIVE: Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real‐world clinical setting. METHODS: Sec...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Obes Sci Pract
Prif Awduron: Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Short Communications
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448201/
https://ncbi.nlm.nih.gov/pubmed/32874678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/osp4.420
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg